skip to Main Content

Emeryville, CA, November 11, 2019 – FlemingMartin is pleased to announce that Gritstone Oncology (NASDAQ: GRTS), an innovative biotechnology company specializing in the development of personalized cancer immunotherapies, has hired James Cho as their Vice President of Finance.

James brings many years of financial leadership in the life sciences to Gritstone, ranging from small companies such as KaloBios Pharmaceuticals and Kodiak Sciences, to his experience in large pharma with Pfizer. In his most recent role, James served as Corporate Controller for UNITY Biotechnology.

At the outset of his career, James spent time as a management consultant with Capgemini and worked for both PwC and KPMG. James is a CPA who earned his MBA in Finance from the University of Southern California and his BS in Accounting from the University of Utah.

 

Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. Gritstone’s approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy tumor cells by targeting tumor-specific neoantigens. To learn more, visit gritstoneoncology.com.

 

FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms, and CEOs of companies to build successful execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital. flemingmartin.com

Back To Top